FOLLOW US

In a move that diffused mounting regulatory pressure, Edwards Drops 'Anti-Copycatting' Policy, prompting European Union antitrust authorities to close a closely watched investigation into the U.S. medical device maker.

The European Commission announced Monday it had ended its probe into Edwards after the company removed the contested policy from its website. However, the commission underscored that shutting down the inquiry does not equate to an endorsement of Edwards’ past conduct under EU competition law.

“After thorough analysis and careful assessment of all evidence gathered, and in light of Edwards Lifesciences' withdrawal of the policy, the commission has concluded that the investigated concerns have been addressed and further action is no longer considered a priority at EU level,” the bloc’s antitrust authority said in a statement.

Inspections and Market Dominance Under Scrutiny

The investigation, which included unannounced inspections at Edwards’ European offices in 2023, focused on whether the company may have abused a dominant market position through its so-called global unilateral pro-innovation — or “anti-copycatting” — policy.

Edwards manufactures heart valve implants designed to improve blood flow by replacing a narrowed aortic valve that fails to open fully. Its policy governed relationships with clinicians and distributors who worked with rival companies producing devices Edwards believed had reverse-engineered its products.

Regulators examined whether the policy’s explicit aim — limiting interactions with so-called “copiers” and those affiliated with them — could distort competition within the bloc.

Policy Targeted Clinicians and Distributors

Under the now-withdrawn framework, Edwards stated it would decline to sponsor clinicians who participated in clinical trials involving competing copycat devices. It also said those clinicians would be excluded from future Edwards-led research initiatives.

The company further indicated it would refuse to distribute its products through distributors that also supplied rival devices deemed to be copies.

The policy itself maintained that Edwards intended to remain compliant with antitrust and intellectual property laws. Still, the commission’s scrutiny signaled concerns that such restrictions could potentially limit market access or penalize stakeholders engaging with competitors.

Edwards did not immediately respond Tuesday to requests for comment.

While the probe has been shelved, the episode serves as a reminder that in highly specialized medical markets — where innovation can mean life-saving advances — the line between protecting intellectual property and restricting competition can be razor thin. For now, Edwards Drops 'Anti-Copycatting' Policy, and with it, at least temporarily, the weight of an EU antitrust investigation.